Welcome to our dedicated page for THERIVA BIOLOGICS SEC filings (Ticker: TOVX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-stage biotech disclosures can be dense. Theriva Biologics’ 10-K leans heavily on R&D milestones, licensing agreements and going-concern analyses, making it tough to spot what really moves the stock. If you have ever typed “Theriva Biologics SEC filings explained simply” or searched for the “Theriva Biologics annual report 10-K simplified,” you know the struggle. Even a single “Theriva Biologics quarterly earnings report 10-Q filing” can run hundreds of pages, while the “Theriva Biologics 8-K material events explained” notices often arrive when trial data shifts overnight.
Stock Titan’s AI-powered analysis cuts through that complexity. Our platform instantly summarizes each document, tags clinical trial milestones and flags liquidity updates, so understanding Theriva Biologics SEC documents with AI becomes straightforward. Real-time alerts ping the moment a “Theriva Biologics Form 4 insider transactions real-time” filing hits EDGAR, letting you view “Theriva Biologics insider trading Form 4 transactions” without digging. Side-by-side views link risk-factor language from the latest 10-K to subsequent 10-Q updates, turning raw text into context you can apply immediately.
Investors tracking the oncolytic adenovirus pipeline care about cash runway, trial enrollment rates and impending readouts. Our comprehensive coverage surfaces those details across every form type: 10-Q segments break down R&D spend; 8-Ks highlight collaboration amendments; the “Theriva Biologics proxy statement executive compensation” section shows how management is incentivized; and “Theriva Biologics executive stock transactions Form 4” entries reveal conviction levels. For deeper “Theriva Biologics earnings report filing analysis,” AI extracts quarter-over-quarter burn rates, while Smart Links connect narrative disclosures to the latest capitalization table. From first 8-K headline to final exhibit, our AI ensures you never miss a material detail.
Two Roads Shared Trust – Anfield Dynamic Fixed Income ETF filed its monthly Form N-PORT for the period ended 30 April 2025. The report covers the Fund’s balance sheet, recent performance, and shareholder activity.
Balance sheet (Part B.1)
- Total assets: $47.01 million
- Total liabilities: $0.05 million
- Net assets: $46.95 million – liabilities represent roughly 0.12 % of assets, indicating a low leverage profile
- Cash & cash equivalents not in Parts C/D: $71 k
Performance (Part B.5)
- Month 1: +1.77 %
- Month 2: -0.33 %
- Month 3: +0.14 %
Flows (Part B.6)
- Month 1 gross sales: $1.48 million; redemptions: $0
- Month 2 gross sales: $0.64 million; redemptions: $0
Risk metrics & leverage: The Fund reported no borrowings, no delayed-delivery payables, and no credit-spread sensitivity disclosures, implying debt exposure remained below the 25 % threshold that would otherwise trigger mandatory reporting.
Key takeaway: The ETF maintains a modest asset base just under $47 million with minimal liabilities and no leverage. Recent flows are positive, though returns have been mixed, reflecting the dynamic fixed-income strategy’s sensitivity to market movements. No information indicates material credit or liquidity stress.
Note: The filing text references Anfield Dynamic Fixed Income ETF, not Hypatia Women CEO ETF (WCEO) cited in the metadata. Analysis is limited to the data explicitly provided in the filing.
Theriva Biologics (NYSE: TOVX) has announced a significant at-the-market (ATM) offering through an amended sales agreement with A.G.P./Alliance Global Partners. The company plans to offer up to $2.53 million worth of common stock through this facility.
Key details of the ATM offering include:
- Sales will be conducted through A.G.P./Alliance Global Partners as Sales Agent
- Sales Agent commission rate set at 3.0% of gross sales price per share
- Offering falls under the previously effective S-3 Registration Statement (File No. 333-279077) from September 2024
- Sales will be made through methods qualifying as "at the market offering" under Rule 415(a)(4)
The filing includes legal validation through Parsons Behle & Latimer's opinion on share validity. This offering provides Theriva with flexibility to raise capital as needed, though there's no obligation to sell any specific amount of shares.
Theriva Biologics (TOVX) has filed a prospectus supplement for an at-market offering of up to $2,534,352 worth of common stock through A.G.P./Alliance Global Partners. The offering is made under an Amended and Restated At Market Issuance Sales Agreement from February 2021, with subsequent amendments.
Key financial details:
- Previous sales: ~569,000 shares generating net proceeds of ~$3.6M in 2024
- Current stock price: $0.465 (as of June 17, 2025)
- Public float value: ~$12.9M based on 9,049,241 non-affiliate shares
- Sales agent commission: up to 3.0% of gross sales
The company, following its March 2022 acquisition of VCN Biosciences, focuses on developing cancer therapeutics. Their lead candidate, VCN-01, is an oncolytic adenovirus currently in Phase 2b trials for pancreatic cancer and Phase 1 studies for retinoblastoma and other solid tumors. The offering is limited by the one-third public float rule under Form S-3 requirements.
FAQ
What is the current stock price of THERIVA BIOLOGICS (TOVX)?
What is the market cap of THERIVA BIOLOGICS (TOVX)?
What is the core therapeutic focus of THERIVA Biologics Inc?
How does the oncolytic adenovirus platform work?
What cancer indications are addressed by THERIVA Biologics?
What makes VCN-01 the lead candidate?
How does THERIVA Biologics differentiate itself from competitors?
What evidence supports the company’s research and clinical development approach?
